1. |
Parkin DM, Bray FI, Devessa SS. Cancer burden for the year 2000: the global picture. Eur J Cancer, 2001, 37(Suppl 8): S4-S66.
|
2. |
American Cancer Society: Cancer facts and figures 2008. [2008- 07-20]. http: //www.cancer.org/.
|
3. |
Non-small lung cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ, 1995, 311(7010): 899-909.
|
4. |
Noble J, Ellis PM, Mackay JA, et al. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol, 2006, 1(9): 1042-1058.
|
5. |
Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall- cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 2000, 18(10): 2095-2103.
|
6. |
Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinumcontaining chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol, 2000, 18(12): 2354-2362.
|
7. |
von Pawel J, Wagner H, Niederle N, et al. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin Oncol, 1996, 23(6 Suppl 16): 47-50.
|
8. |
Nakamura Y, Kunitoh H, Kubota K, et al. Retrospective analysis of safety and efficacy of low-dose docetaxel 60 mg/m2 in advanced non-small cell lung cancer patients previously treated with platinum- based chemotherapy. Am J Clin Oncol, 2003, 26(5): 459-464.
|
9. |
Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer . J Clin Oncol, 1998, 16(10) : 3353-3361.
|
10. |
Lilenbaum RC, Schwartz MA, Seigel L, et al. Phase II trial of weekly docetaxel in second-line therapy for non-small cell lung carcinoma. Cancer, 2001, 92(8): 2158-2163.
|
11. |
Belani CP, Dakhil S, Waterhouse DM, et al. Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Ann Oncol, 2007, 18(1): 110-115.
|
12. |
Socinski MA, Ivanova A, Bakri K, et al. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol, 2006, 17(1): 104-109.
|
13. |
Camps C, Massuti B, Jiménez A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced nonsmall- cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol, 2006, 17(3): 467-472.
|
14. |
Chen YM, Shih JF, Perng RP, et al. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest, 2006, 129(4): 1031-1038.
|
15. |
Gervais R, Ducolone A, Breton JL, et al. Phase II randomized trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol, 2005, 16(1): 90-96.
|
16. |
Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL01 study. Br J Cancer, 2004, 91(12): 1996-2004.
|
17. |
Lai CL, Tsai CM, Chiu CH, et al. Phase II randomized trial of triweekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer. Jpn J Clin Oncol, 2005, 35(12): 700-706.
|
18. |
Schuette W, Nagel S, Blankenburg T, et al. Phase III study of secondline chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol, 2005, 23(33): 8389-8395.
|
19. |
Lilenbaum R, Rubin M, Samuel J, et al. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol, 2007, 2(4): 306-311.
|
20. |
Massimo DM, Francesco P, Paolo C, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced nonsmall- cell lung cancer. J Clin Oncol, 2007 25(11): 1377-1382.
|